{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T22:33:08Z","timestamp":1770330788716,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:00:00Z","timestamp":1696032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Saudi Pharmaceutical Journal"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jsps.2023.101813","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T09:28:01Z","timestamp":1696498081000},"page":"101813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness, safety, and cost of vancomycin and linezolid in Kuwait: A retrospective cohort study"],"prefix":"10.1007","volume":"31","author":[{"given":"Sarah S.","family":"Alghanem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moetaza M.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Al-Manie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wadha","family":"Alfouzan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duaa","family":"Alhammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousif","family":"Alreshidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Hajjiah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafaa","family":"Alfarhoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Almane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Mataqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salma","family":"Alajmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalifa","family":"Albenwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10.1016\/j.jsps.2023.101813_b0005","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2991\/jegh.k.210524.001","article-title":"Epidemiology and microbiological profile of common healthcare associated infections among patients in the intensive care unit of a general hospital in Kuwait: A retrospective observational study","volume":"1","author":"Alfouzan","year":"2021","journal-title":"J. Epidemiol. Glob. Health"},{"key":"10.1016\/j.jsps.2023.101813_b0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12941-021-00450-x","article-title":"Antimicrobial susceptibility of gram-positive and gram-negative bacteria: A 5-year retrospective analysis at a multi-hospital healthcare system in Saudi Arabia","volume":"20","author":"Alhumaid","year":"2021","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"10.1016\/j.jsps.2023.101813_b0015","doi-asserted-by":"crossref","first-page":"220","DOI":"10.5492\/wjccm.v10.i5.220","article-title":"Trends of central line-associated bloodstream infections in the intensive care unit in the Kingdom of Bahrain: Four years' experience","volume":"10","author":"Al-Khawaja","year":"2021","journal-title":"World J. Crit. Care Med."},{"key":"10.1016\/j.jsps.2023.101813_b0020","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(10)61458-4","article-title":"Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis","volume":"377","author":"Allegranzi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jsps.2023.101813_b0025","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ajic.2015.10.031","article-title":"Device-associated infection rates, bacterial resistance, length of stay, and mortality in Kuwait: International Nosocomial Infection Consortium findings","volume":"44","author":"Al-Mousa","year":"2016","journal-title":"Am. J. Infect. Control"},{"key":"10.1016\/j.jsps.2023.101813_b0030","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ijid.2020.09.1481","article-title":"Prevalence of infections and antimicrobial use in the acute-care hospital setting in the Middle East: Results from the first point-prevalence survey in the region","volume":"101","author":"Alothman","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.jsps.2023.101813_b0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijantimicag.2009.09.013","article-title":"Linezolid versus vancomycin for the treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials","volume":"35","author":"Beibei","year":"2010","journal-title":"Inter. J. Antimicrob. Agents"},{"key":"10.1016\/j.jsps.2023.101813_b0040","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jval.2010.12.006","article-title":"Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: Complicated skin and skin structure infection using Bayesian methods for evidence synthesis","volume":"14","author":"Bounthavong","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jsps.2023.101813_b0045","article-title":"Teicoplanin versus vancomycin for proven or suspected infection","volume":"6","author":"Cavalcanti","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jsps.2023.101813_b0050","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s15010-008-8046-7","article-title":"Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany","volume":"37","author":"De Cock","year":"2009","journal-title":"Infection"},{"key":"10.1016\/j.jsps.2023.101813_b0055","first-page":"1","article-title":"Improving Global Outcomes (KDIGO) acute kidney injury work group. KDIGO Clinical Practice Guideline for acute kidney injury","volume":"2","author":"Disease","year":"2012","journal-title":"Kidney Inter."},{"key":"10.1016\/j.jsps.2023.101813_b0060","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1473-3099(07)70312-2","article-title":"Linezolid versus glycopeptide or \u03b2-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials","volume":"8","author":"Falagas","year":"2008","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jsps.2023.101813_b0065","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s10096-013-1867-z","article-title":"Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials","volume":"32","author":"Jiang","year":"2013","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.jsps.2023.101813_b0070","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1097\/CCM.0b013e3181eb3b96","article-title":"Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: A systematic review and meta-analysis","volume":"38","author":"Kalil","year":"2010","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.jsps.2023.101813_b0075","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jgar.2020.12.009","article-title":"Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus","volume":"24","author":"Kato","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"10.1016\/j.jsps.2023.101813_b0080","doi-asserted-by":"crossref","first-page":"19688","DOI":"10.2807\/ese.15.41.19688-en","article-title":"Methicillin-resistant Staphylococcus aureus (MRSA): Burden of disease and control challenges in Europe","volume":"15","author":"K\u00f6ck","year":"2010","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.jsps.2023.101813_b0085","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1592\/phco.21.11.1010.34517","article-title":"Hematologic effects of antimicrobials: Focus on the oxazolidinone linezolid","volume":"21","author":"Kuter","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jsps.2023.101813_b0090","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1469-0691.2012.03914.x","article-title":"The economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)","volume":"19","author":"Lee","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.jsps.2023.101813_b0095","unstructured":"Ministry of Health. (2016-2017) Cost Analysis and Performance Evaluation for Government Health Services. Kuwait: Ministry of Health; 2017."},{"key":"10.1016\/j.jsps.2023.101813_b0100","article-title":"Tackling drug-resistant infections globally: Final report and recommendations","author":"O\u2019Neill","year":"2016","journal-title":"Rev. Antimicrob. Resist."},{"key":"10.1016\/j.jsps.2023.101813_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijmm.2021.151477","article-title":"Emergence of linezolid-resistance in vancomycin-resistant Enterococcus faecium ST117 associated with increased linezolid-consumption","volume":"311","author":"Olearo","year":"2021","journal-title":"Int. J. Med. Microbiol."},{"key":"10.1016\/j.jsps.2023.101813_b0110","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jiac.2020.06.006","article-title":"Teicoplanin and therapeutic drug monitoring: An update for optimal use in different patient populations","volume":"26","author":"Pea","year":"2020","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.jsps.2023.101813_b0115","first-page":"1800393","article-title":"Antimicrobial use in European acute care hospitals: results from the second point prevalence survey (PPS) of healthcare-associated infections and antimicrobial use, 2016 to 2017","volume":"23","author":"Plachouras","year":"2018","journal-title":"Eurosurveillance Weekly"},{"key":"10.1016\/j.jsps.2023.101813_b0120","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/FTD.0000000000000710","article-title":"Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: A review of linezolid pharmacokinetics and pharmacodynamics","volume":"42","author":"Rao","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jsps.2023.101813_b0125","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jiph.2020.03.012","volume":"13","author":"Rosenthal","year":"2020","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/j.jsps.2023.101813_b0130","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.jsps.2023.101813_b0135","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1099\/jmm.0.04949-0","article-title":"Species prevalence and antibacterial resistance of enterococci isolated in Kuwait hospitals","volume":"52","author":"Udo","year":"2003","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.jsps.2023.101813_b0140","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1159\/000481944","article-title":"Antibiotic resistance trends in Methicillin-Resistant Staphylococcus aureus isolated in Kuwait hospitals: 2011\u20132015","volume":"26","author":"Udo","year":"2017","journal-title":"Med. Princ. Pract."},{"key":"10.1016\/j.jsps.2023.101813_b0145","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1155\/2014\/279794","article-title":"Financial impact of health care-associated infections: When money talks","volume":"25","author":"Valiquette","year":"2014","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"key":"10.1016\/j.jsps.2023.101813_b0150","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1378\/chest.10-1556","article-title":"Linezolid vs glycopeptide antibiotics for the treatment of suspected Methicillin-Resistant Staphylococcus aureus nosocomial pneumonia: A meta-analysis of randomized controlled trials","volume":"139","author":"Walkey","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.jsps.2023.101813_b0155","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00228-014-1775-x","article-title":"Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis","volume":"71","author":"Wang","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jsps.2023.101813_b0160","doi-asserted-by":"crossref","unstructured":"Yue J, Dong BR, Yang M, et al. Linezolid versus vancomycin for skin and soft tissue infections. Cochrane Database Syst Rev. 2016:Cd008056.","DOI":"10.1002\/14651858.CD008056.pub3"},{"key":"10.1016\/j.jsps.2023.101813_b0165","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1038\/s41598-020-60825-6","article-title":"Clinical and economic impact of methicillin-resistant Staphylococcus aureus: A multicentre study in China","volume":"10","author":"Zhen","year":"2020","journal-title":"Sci. Rep."}],"container-title":["Saudi Pharmaceutical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016423003080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016423003080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:29:00Z","timestamp":1736184540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1319016423003080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1319016423003080"],"URL":"https:\/\/doi.org\/10.1016\/j.jsps.2023.101813","relation":{},"ISSN":["1319-0164"],"issn-type":[{"value":"1319-0164","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness, safety, and cost of vancomycin and linezolid in Kuwait: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Saudi Pharmaceutical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsps.2023.101813","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of King Saud University.","name":"copyright","label":"Copyright"}],"article-number":"101813"}}